Arnon Nagler

71.7k total citations · 8 hit papers
1.1k papers, 39.3k citations indexed

About

Arnon Nagler is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Arnon Nagler has authored 1.1k papers receiving a total of 39.3k indexed citations (citations by other indexed papers that have themselves been cited), including 750 papers in Hematology, 311 papers in Oncology and 256 papers in Immunology. Recurrent topics in Arnon Nagler's work include Hematopoietic Stem Cell Transplantation (546 papers), Acute Myeloid Leukemia Research (340 papers) and Acute Lymphoblastic Leukemia research (227 papers). Arnon Nagler is often cited by papers focused on Hematopoietic Stem Cell Transplantation (546 papers), Acute Myeloid Leukemia Research (340 papers) and Acute Lymphoblastic Leukemia research (227 papers). Arnon Nagler collaborates with scholars based in Israel, France and United States. Arnon Nagler's co-authors include Avichai Shimoni, Reuven Or, Tsvee Lapidot, Mohamad Mohty, Amnon Peled, Myriam Labopin, Isabelle Petit, Shimon Slavin, E Naparstek and Aliza Ackerstein and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Arnon Nagler

1.1k papers receiving 38.6k citations

Hit Papers

Nonmyeloablative Stem Cel... 1989 2026 2001 2013 1998 1998 1999 2002 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
    1998 1.6k citations Arnon Nagler, Gàbor Varadi et al. profile →
  2. Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
    1998 1.5k citations Arnon Nagler, Gàbor Varadi et al. profile →
  3. Dependence of Human Stem Cell Engraftment and Repopulation of NOD/SCID Mice on CXCR4
    1999 1.4k citations Amnon Peled, Arnon Nagler et al. profile →
  4. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4
    2002 1.1k citations Arnon Nagler, Amnon Peled et al. profile →
  5. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice
    2000 603 citations Amnon Peled, Arnon Nagler et al. profile →
  6. Comparative studies of human FcRIII-positive and negative natural killer cells.
    1989 583 citations Arnon Nagler et al. profile →
  7. Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
    2008 536 citations Maya Koren‐Michowitz, Avichai Shimoni et al. Clinical Cancer Research profile →
  8. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
    2007 505 citations Arnon Nagler et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arnon Nagler Israel 88 21.6k 12.6k 12.5k 7.8k 6.0k 1.1k 39.3k
Richard E. Champlin United States 113 27.2k 1.3× 12.6k 1.0× 14.9k 1.2× 6.7k 0.9× 8.4k 1.4× 1.1k 45.3k
Daniel J. Weisdorf United States 96 24.2k 1.1× 13.3k 1.1× 11.4k 0.9× 5.1k 0.7× 5.1k 0.8× 732 38.4k
Sergio Giralt United States 86 21.4k 1.0× 7.0k 0.6× 10.0k 0.8× 5.6k 0.7× 5.0k 0.8× 856 30.2k
Jerome Ritz United States 103 12.9k 0.6× 19.0k 1.5× 10.1k 0.8× 6.4k 0.8× 4.8k 0.8× 610 36.4k
Stephen J. Forman United States 100 12.3k 0.6× 9.1k 0.7× 16.3k 1.3× 8.1k 1.1× 4.5k 0.8× 861 36.2k
Franco Locatelli Italy 88 12.5k 0.6× 9.9k 0.8× 8.4k 0.7× 7.6k 1.0× 8.1k 1.3× 1.0k 33.0k
Gèrard Socié France 91 18.7k 0.9× 9.2k 0.7× 7.4k 0.6× 3.4k 0.4× 4.8k 0.8× 701 30.2k
Éliane Gluckman France 93 19.2k 0.9× 7.8k 0.6× 6.5k 0.5× 4.6k 0.6× 6.9k 1.2× 627 29.5k
Joseph H. Antin United States 90 17.8k 0.8× 9.5k 0.8× 6.4k 0.5× 2.7k 0.3× 3.8k 0.6× 491 28.0k
Bruce R. Blazar United States 119 20.2k 0.9× 36.0k 2.9× 16.5k 1.3× 9.4k 1.2× 5.0k 0.8× 843 58.3k

Countries citing papers authored by Arnon Nagler

Since Specialization
Citations

This map shows the geographic impact of Arnon Nagler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnon Nagler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnon Nagler more than expected).

Fields of papers citing papers by Arnon Nagler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnon Nagler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnon Nagler. The network helps show where Arnon Nagler may publish in the future.

Co-authorship network of co-authors of Arnon Nagler

This figure shows the co-authorship network connecting the top 25 collaborators of Arnon Nagler. A scholar is included among the top collaborators of Arnon Nagler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnon Nagler. Arnon Nagler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Youngster, Ilan, Ivetta Danylesko, Israel Henig, et al.. (2024). Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study. Bone Marrow Transplantation. 59(3). 409–416. 7 indexed citations
3.
Allen, Daniel, Lucien E. Weiss, Michael A. Rosenberg, et al.. (2022). High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells. The CRISPR Journal. 5(1). 80–94. 16 indexed citations
4.
Díaz‐Beyá, Marina, Myriam Labopin, Johan Maertens, et al.. (2020). Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology. 189(5). 920–925. 14 indexed citations
5.
6.
Baron, Frédéric, Myriam Labopin, Didier Blaise, et al.. (2020). Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation. 56(2). 461–469. 2 indexed citations
7.
Itzhaki, Orit, Elad Jacoby, Arnon Nagler, et al.. (2020). Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. Journal for ImmunoTherapy of Cancer. 8(1). e000148–e000148. 37 indexed citations
8.
Bazarbachi, Ali, Christoph Schmid, Myriam Labopin, et al.. (2020). Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research. 26(24). 6475–6482. 39 indexed citations
9.
Poiré, Xavier, Myriam Labopin, Emmanuelle Polge, et al.. (2019). Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Haematologica. 105(2). 414–423. 8 indexed citations
10.
Shouval, Roni, Annalisa Ruggeri, Myriam Labopin, et al.. (2017). An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research. 23(21). 6478–6486. 25 indexed citations
11.
Abraham, Michal, Yaron Pereg, Baruch Bulvik, et al.. (2017). Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers. Clinical Cancer Research. 23(22). 6790–6801. 41 indexed citations
12.
Beider, Katia, Merav Darash‐Yahana, Maya Koren‐Michowitz, et al.. (2014). Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo. Molecular Cancer Therapeutics. 13(5). 1155–1169. 51 indexed citations
13.
Peled, Amnon, Michal Abraham, Irit Avivi, et al.. (2013). The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma. Clinical Cancer Research. 20(2). 469–479. 70 indexed citations
14.
Beider, Katia, Elena Ribakovsky, Michal Abraham, et al.. (2013). Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140. Clinical Cancer Research. 19(13). 3495–3507. 48 indexed citations
15.
16.
17.
Besser, Michal J., Ronnie Shapira‐Frommer, Avraham J. Treves, et al.. (2010). Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research. 16(9). 2646–2655. 352 indexed citations
18.
Canals, Carmen, H. Schouten, Arnon Nagler, et al.. (2009). Allogeneic stem cell transplantation as salvage therapy in patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem cell transplantation. An analysis of the EBMT Registry. Bone Marrow Transplantation. 43. 2 indexed citations
19.
Pinthus, Jehonathan H., Arnon Nagler, Eddie Fridman, et al.. (2005). INHIBITION OF WILMS TUMOR XENOGRAFT PROGRESSION BY HALOFUGINONE IS ACCOMPANIED BY ACTIVATION OF WT-1 GENE EXPRESSION. The Journal of Urology. 174(4 Part 2). 1527–1531. 25 indexed citations
20.
Varadi, Gàbor, et al.. (1995). Umbilical Cord Blood For Use in Transplantation. Obstetrical & Gynecological Survey. 50(8). 611–617. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard E. Champlin Breakdown of academic impact, for papers by Daniel J. Weisdorf Breakdown of academic impact, for papers by Sergio Giralt Breakdown of academic impact, for papers by Jerome Ritz Breakdown of academic impact, for papers by Stephen J. Forman Breakdown of academic impact, for papers by Franco Locatelli Breakdown of academic impact, for papers by Gèrard Socié Breakdown of academic impact, for papers by Éliane Gluckman Breakdown of academic impact, for papers by Joseph H. Antin Breakdown of academic impact, for papers by Bruce R. Blazar
Rankless by CCL
2026